By Michael Erman (Reuters) - Merck & Co said on Wednesday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales .
Merck (NYSE: MRK) sold USD952 Million of molnupiravir, its Covid-19 treatment pill, during the fourth quarter and is set to sell an additional USD5 Billion to USD6 Billion this year.
Merck & Co , Inc s (MRK) Buy Rating Reaffirmed at Mizuho etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.